P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN'S LYMPHOMA. (23rd June 2022) - Leabman, M. K.; Hernandez, G.; Ng, C. M.; Tang, J.; Pandya, D.; Hart, K. C.; Li, K.; Hinton, P. R.; So, J.; Qazi, I.; Cheah, C. Y.; Kim, W. S.; et al.